AU2012289429B2 - Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof - Google Patents

Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof Download PDF

Info

Publication number
AU2012289429B2
AU2012289429B2 AU2012289429A AU2012289429A AU2012289429B2 AU 2012289429 B2 AU2012289429 B2 AU 2012289429B2 AU 2012289429 A AU2012289429 A AU 2012289429A AU 2012289429 A AU2012289429 A AU 2012289429A AU 2012289429 B2 AU2012289429 B2 AU 2012289429B2
Authority
AU
Australia
Prior art keywords
polymorph
compound
formula
diffraction pattern
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012289429A
Other languages
English (en)
Other versions
AU2012289429A1 (en
AU2012289429A8 (en
Inventor
Yunyan Hu
Xinshan Kang
Wei LONG
Yinxiang Wang
Jianxi ZHANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Betta Pharmaceuticals Co Ltd
Original Assignee
Beijing Betta Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Betta Pharmaceuticals Co Ltd filed Critical Beijing Betta Pharmaceuticals Co Ltd
Publication of AU2012289429A1 publication Critical patent/AU2012289429A1/en
Publication of AU2012289429A8 publication Critical patent/AU2012289429A8/en
Application granted granted Critical
Publication of AU2012289429B2 publication Critical patent/AU2012289429B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AU2012289429A 2011-07-22 2012-07-23 Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof Active AU2012289429B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN201110207175.6 2011-07-22
CN201110207175 2011-07-22
CN201110209657.5 2011-07-25
CN201110209657 2011-07-25
CN201110211297 2011-07-26
CN201110211297.2 2011-07-26
PCT/CN2012/079058 WO2013013609A1 (en) 2011-07-22 2012-07-23 Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof

Publications (3)

Publication Number Publication Date
AU2012289429A1 AU2012289429A1 (en) 2014-03-20
AU2012289429A8 AU2012289429A8 (en) 2014-05-22
AU2012289429B2 true AU2012289429B2 (en) 2016-07-28

Family

ID=47600518

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012289429A Active AU2012289429B2 (en) 2011-07-22 2012-07-23 Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof

Country Status (11)

Country Link
US (1) US9206134B2 (https=)
EP (1) EP2734504B1 (https=)
JP (1) JP6099644B2 (https=)
KR (1) KR102029951B1 (https=)
CN (1) CN104024227B8 (https=)
AU (1) AU2012289429B2 (https=)
CA (1) CA2842730C (https=)
ES (1) ES2606631T3 (https=)
IL (1) IL230580B (https=)
WO (1) WO2013013609A1 (https=)
ZA (1) ZA201401310B (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2528232C (en) 2003-06-06 2010-05-25 Fibrogen, Inc. Novel nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
NO2686520T3 (https=) 2011-06-06 2018-03-17
EP2872487B1 (en) * 2012-07-16 2017-04-26 Fibrogen, Inc. Process for making isoquinoline compounds
KR20210130849A (ko) * 2012-07-16 2021-11-01 피브로겐, 인크. 프롤릴 하이드록실라제 억제제 [(4-하이드록시-1-메틸-7-페녹시-아이소퀴놀린-3-카보닐)-아미노]-아세트산의 결정형
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
KR20210104173A (ko) 2013-06-06 2021-08-24 피브로겐, 인크. Hif 하이드록실라제 억제자의 약학적 제형
SG10201910773VA (en) 2013-06-13 2020-01-30 Akebia Therapeutics Inc Compositions and methods for treating anemia
AR099354A1 (es) * 2013-11-15 2016-07-20 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos
CN103694172A (zh) * 2013-12-26 2014-04-02 辽宁亿灵科创生物医药科技有限公司 含氮杂芳基化合物的衍生物
AU2016209126A1 (en) 2015-01-23 2017-08-10 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
CN106146490B (zh) * 2015-03-27 2018-10-23 沈阳三生制药有限责任公司 被芳氧基或杂芳氧基取代的5-羟基-1,7-萘啶化合物、其制备方法及其制药用途
US11324734B2 (en) 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
CN104910113B (zh) * 2015-05-21 2017-05-10 中国科学院宁波材料技术与工程研究所 一种羟基苯酐的制备方法
CN104892509B (zh) * 2015-06-04 2018-03-09 苏州明锐医药科技有限公司 诺得司他的制备方法
US10450569B2 (en) 2015-08-13 2019-10-22 Somagenics, Inc. Methods and compositions of short small hairpin RNAS and microRNAS for wound healing
CN105130888A (zh) 2015-10-09 2015-12-09 中国药科大学 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途
CN106916105A (zh) * 2015-12-28 2017-07-04 徐州万邦金桥制药有限公司 一种纯化可博美的方法
CN106187888A (zh) * 2016-07-18 2016-12-07 江苏德源药业股份有限公司 Fg‑4592单晶及其制备方法
CZ2016627A3 (cs) 2016-10-07 2018-04-18 Zentiva, K.S. Způsob přípravy (7-fenoxy-4-hydroxy-1-methylisochinolin-3-karbonyl)glycinu (roxadustatu) a jeho intermediátů založený na souběžném otevírání oxazolového kruhu, štěpení etheru a tvorbě iminu
CN107954931B (zh) * 2016-10-17 2021-06-22 上海医药集团青岛国风药业股份有限公司 一种诺得司他的制备方法
CN108017583B (zh) * 2016-11-01 2021-04-06 徐州万邦金桥制药有限公司 一种可博美的制备方法
WO2019030711A1 (en) * 2017-08-11 2019-02-14 Dr. Reddy’S Laboratories Limited POLYMORPHS AND CO-CRYSTALS OF ROXADUSTAT
US11192860B2 (en) * 2017-09-04 2021-12-07 Sandoz Ag Co-crystal of an orally available HIF prolyl hydroxylase inhibitor
CA3083672A1 (en) * 2017-12-01 2019-06-06 Dr. Reddy's Laboratories Limited Process for the preparation of roxadustat and its intermediates
CN109956870A (zh) * 2017-12-14 2019-07-02 南京卡文迪许生物工程技术有限公司 一种罗沙司他的合成方法及其中间体化合物
CN108059679B (zh) * 2017-12-27 2020-03-24 吉林大学 一种人源单链抗体及其应用
CN110218184B (zh) * 2018-03-01 2022-09-27 广东东阳光药业有限公司 诺德司他共晶及其制备方法
CN115246789B (zh) * 2018-03-16 2023-10-17 上海医药集团青岛国风药业股份有限公司 一种诺得司他的制备方法
CN108424388B (zh) * 2018-04-19 2020-08-21 杭州科巢生物科技有限公司 一种慢性贫血药物的制备方法
EP3790863A1 (en) 2018-05-09 2021-03-17 Akebia Therapeutics Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
CN110903242B (zh) * 2018-09-14 2023-05-12 四川科伦药物研究院有限公司 罗沙司他中间体的制备方法
CN109369525A (zh) * 2018-12-29 2019-02-22 安礼特（上海）医药科技有限公司 罗沙司它的新晶型及其制备方法
WO2020178847A1 (en) 2019-03-01 2020-09-10 Mylan Laboratories Limited Cocrystal of roxadustat and d-proline
CN109776415B (zh) * 2019-03-07 2020-11-17 福建南方制药股份有限公司 一种Roxadustat中间体的制备方法
IL287258B2 (en) 2019-04-18 2026-01-01 Nikang Therapeutics Inc Inhibitors as tetrahydro-1h-cyclopenta[cd] indene derivatives as hypoxia inducible factor -2alpha
CN109956901B (zh) * 2019-04-25 2022-09-06 南京正大天晴制药有限公司 异喹啉酮类化合物的制备方法
US20220340532A1 (en) 2019-08-07 2022-10-27 Teva Pharmaceuticals International Gmbh Processes for the preparation of roxadustat and intermediates thereof
CN112679428A (zh) * 2019-10-17 2021-04-20 罗欣药业(上海)有限公司 罗沙司他新晶型及其制备方法
CN112679430B (zh) * 2019-10-18 2023-05-05 上海迪赛诺化学制药有限公司 一种制备异喹啉酮类化合物的方法
CN112679431B (zh) * 2019-10-18 2023-05-05 上海迪赛诺化学制药有限公司 一种制备异喹啉酮类化合物的方法
CN112679429B (zh) * 2019-10-18 2023-05-05 上海迪赛诺化学制药有限公司 一种制备异喹啉酮类化合物的方法
WO2021073623A1 (zh) * 2019-10-18 2021-04-22 上海迪赛诺化学制药有限公司 一种制备异喹啉酮类化合物的方法
JP2022553706A (ja) 2019-10-22 2022-12-26 ▲蘇▼州科睿思制▲葯▼有限公司 低酸素誘導因子－プロリルヒドロキシラーゼ阻害剤の結晶形
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
CN111205224B (zh) * 2020-04-22 2020-08-25 南京佰麦生物技术有限公司 一种罗沙司他水合物的晶型及其制备方法和应用
CN113801060B (zh) * 2020-06-13 2025-06-27 苏州鹏旭医药科技有限公司 一种多取代异喹啉化合物的制备方法
EP4169906B1 (en) 2020-06-19 2024-09-04 Jumpcan (Shanghai) Medical Technology Co., Ltd Method for synthesis of roxadustat and intermediate thereof, and intermediate thereof
CN112500344B (zh) * 2020-11-18 2022-07-01 江苏豪森药业集团有限公司 罗沙司他晶型及其制备方法
CN112194624A (zh) * 2020-11-18 2021-01-08 江苏豪森药业集团有限公司 一种异喹啉类化合物的晶型及其制备方法
CN115144480B (zh) * 2021-03-31 2023-11-28 成都倍特药业股份有限公司 一种从罗沙司他中间体中检测吗啉和/或四甲基甲烷二胺的方法
CN115724796A (zh) * 2021-08-26 2023-03-03 成都苑东生物制药股份有限公司 一种罗沙司他新晶型及其制备方法
WO2023095162A1 (en) 2021-11-26 2023-06-01 Mylan Laboratories Limited Cocrystal of roxadustat and nicotinamide

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108681A1 (en) * 2003-06-06 2004-12-16 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
CN101394843A (zh) * 2005-06-06 2009-03-25 菲布罗根公司 使用HIFα稳定剂的改进的贫血治疗
CN101500569A (zh) * 2006-06-15 2009-08-05 菲布罗根公司 用于治疗癌症贫血的hif羟化酶抑制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5470285A (en) * 1977-11-14 1979-06-05 Tanabe Seiyaku Co Ltd Production of 4-hydroxyisocarbostyryl-3-carboxylic analog
DE19746287A1 (de) * 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US7893071B2 (en) * 2001-04-23 2011-02-22 University Of Virginia Patent Foundation Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic
US7189697B2 (en) 2004-04-13 2007-03-13 Trustees Of Tufts College Compositions and uses of a galectin for treatment of dry eye syndrome
JP5202327B2 (ja) 2005-12-09 2013-06-05 アムジエン・インコーポレーテツド プロリルヒドロキシラーゼ阻害活性を示すキノロンベースの化合物、およびこの組成物、およびこの使用
EP2476669A1 (en) * 2006-01-27 2012-07-18 Fibrogen, Inc. Cyanoisoquinoline compounds and methods of use thereof
JP4311416B2 (ja) 2006-06-30 2009-08-12 株式会社日立製作所 渦電流探傷法による表面欠陥長さ評価方法
AU2010273101B2 (en) 2009-07-15 2016-02-25 Beijing Betta Pharmaceuticals Co., Ltd. Compounds as hypoxia mimetics, and compositions, and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108681A1 (en) * 2003-06-06 2004-12-16 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
CN101394843A (zh) * 2005-06-06 2009-03-25 菲布罗根公司 使用HIFα稳定剂的改进的贫血治疗
CN101500569A (zh) * 2006-06-15 2009-08-05 菲布罗根公司 用于治疗癌症贫血的hif羟化酶抑制剂

Also Published As

Publication number Publication date
IL230580A0 (en) 2014-03-31
CN104024227A (zh) 2014-09-03
JP6099644B2 (ja) 2017-03-22
ES2606631T3 (es) 2017-03-24
AU2012289429A1 (en) 2014-03-20
KR20140049004A (ko) 2014-04-24
ZA201401310B (en) 2015-04-29
US9206134B2 (en) 2015-12-08
WO2013013609A1 (en) 2013-01-31
US20150031721A1 (en) 2015-01-29
EP2734504A4 (en) 2014-12-31
EP2734504A1 (en) 2014-05-28
IL230580B (en) 2019-07-31
CA2842730A1 (en) 2013-01-31
CN104024227B8 (zh) 2025-07-29
CN104024227B (zh) 2015-12-02
CA2842730C (en) 2018-08-21
JP2014524920A (ja) 2014-09-25
KR102029951B1 (ko) 2019-11-08
EP2734504B1 (en) 2016-09-14

Similar Documents

Publication Publication Date Title
AU2012289429B2 (en) Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
JP7105430B1 (ja) ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物
US12383535B2 (en) Hydrogen peroxide-responsive KEAP1-NRF2 ppi inhibitor prodrug, and preparation method therefor
CA2767911C (en) Compounds as hypoxia mimetics, and compositions, and uses thereof
WO2018041260A1 (zh) 一类溴结构域识别蛋白抑制剂及其制备方法和用途
JP2023077412A (ja) ウイルス増殖阻害作用を有するトリアジン誘導体の製造方法
US9238637B2 (en) Stable polymorphic forms of compound as hypoxia mimetics, and uses thereof
TWI582078B (zh) 抑制脯氨酸羥化酶活性的化合物的晶型及其應用
CN115304597B (zh) 一类β-咔啉类化合物及其在制备治疗或预防肿瘤疾病的药物中的应用
TWI424842B (zh) 含取代基的雜環化合物、包括其的藥物組合物，以及該化合物的應用
TW201736373A (zh) 作為免疫調節劑的三並環化合物
JP5975122B2 (ja) ［（４−ヒドロキシ−２−オキソ−１，２，５，６−テトラヒドロ−３−ピリジニル）カルボニル］グリシン化合物の結晶形及びそれらの製造方法
WO2023192864A2 (en) Covalent parp16 inhibitors
KR820000493B1 (ko) 퀴나졸린 유도체의 제조방법
TW201321361A (zh) 抑制脯氨酸羥化酶活性的化合物的穩定晶型及其應用
CN110172052A (zh) 一种苯并吡喃酮衍生物的制备工艺与应用
HK1161234B (en) Compounds as hypoxia mimetics, and compositions, and uses thereof

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 28 , NO 11 , PAGE(S) 1491 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME BEIJING BETTA PHARMACEUTICALS CO.,LTD, APPLICATION NO. 2012289429, UNDER INID (71) CORRECT THE APPLICANT NAME TO BEIJING BETTA PHARMACEUTICALS CO., LTD

FGA Letters patent sealed or granted (standard patent)